[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581333":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":22,"id":56,"slug":22,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":22,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":22,"enrollmentInfo":64,"targetDuration":22,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":22,"overallStatus":39,"whyStopped":22,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery","ACTIVE_COMPARATOR",[12],"Combination Product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery",{"label":14,"type":15,"description":14,"interventionNames":16},"Sham procedure in conjunction with cataract surgery","SHAM_COMPARATOR",[17],"Procedure: Sham procedure in conjunction with cataract surgery",[19,23],{"type":20,"name":9,"description":9,"armGroupLabels":21,"otherNames":22},"COMBINATION_PRODUCT",[9],null,{"type":24,"name":14,"description":14,"armGroupLabels":25,"otherNames":22},"PROCEDURE",[14],[27],{"name":28,"affiliation":5,"role":29},"Study Director","STUDY_CHAIR",[31],{"name":32,"role":33,"phone":34,"phoneExt":22,"email":35},"Study Manager","CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Glaukos Investigator Site","RECRUITING","Kenosha","Wisconsin","53142","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-87.82119,42.58474,{"lat":49,"lon":48},[52],{"name":22,"role":33,"phone":22,"phoneExt":22,"email":53},"idose@glaukos.com",{"type":55,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100581333",false,"NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone","Inclusion Criteria:\n\n* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.\n* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)\n\nExclusion Criteria:\n\n* Active corneal inflammation or edema.\n* Retinal disorders not associated with glaucoma.","ALL","45 Years",{"count":65,"type":66},132,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone",[72,73,74],"Glaucoma, Open-angle","Ocular Hypertension (OHT)","Phacoemulsification Cataract Surgery","2026-01-19",{"date":77,"type":78},"2026-01-21","ACTUAL",{"date":80,"type":78},"2025-01-13",{"date":82,"type":66},"2027-06",{"name":5,"class":6},1]